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Ubiquitination was first recognized for its function in 
tagging proteins for destruction by the proteasome [1-5], 
but is now known to be one of the major types of post-
translational modifications necessary for proper 
functioning of signaling cascades [6-8]. The attachment 
of ubiquitin molecules to their targets occurs through 
reactions mediated by proteins of three classes, acting in 
sequence: a ubiquitin-activating enzyme, E1, which 
contains an active-site cysteine to which the carboxy-
terminal glycine of ubiquitin becomes attached through a 
reactive thioester bond; a ubiquitin-conjugating enzyme, 
the E2, to which the ubiquitin is transferred by an 
analogous reaction; and a ubiquitin ligase, the E3, which 
catalyzes the attachment of the ubiquitin to a lysine in 
the target protein [4,5,9-11]. Seven of the 76 amino acids 
of ubiquitin are lysines, which can themselves be targeted 
by ubiquitination to generate polyubiquitin chains of 
different linkage types depending on which lysine residue 
acts as the acceptor site for the incoming ubiquitin [12-
14]. In an exception to this pattern, linear ubiquitin 
chains can be generated by the formation of a peptide 
bond between the carboxy-terminal glycine of the 
incoming and the amino-terminal methionine residue of 
the preceding ubiquitin molecule [15]. Recent research 
has established the identity and composition of an E3 
ubiquitin ligase that generates linear ubiquitin chains, 
and has shown that these chains play an important part 
in several innate and adaptive immune signaling 
pathways, including the one triggered by tumor necrosis 
factor (TNF) [16-21]. Here we review what is known 
about the process by which linear ubiquitin chains are 
assembled, and how they contribute to TNF receptor 1 
(TNFR1) signaling.
LUBAC and the assembly of linear ubiquitin chains
The assembly of linear ubiquitin chains is unusual in 
three ways. First, as we have already mentioned, the 
linkage does not involve any of the lysine residues in the 
ubiquitin molecule, but occurs between the amino-
terminal methionine of one ubiquitin and the carboxy-
terminal glycine of the next in the chain. For this reason, 
linear ubiquitin chains are also known as M1-linked 
chains. The second unusual feature of linear ubiquitin 
chain assembly is that it is the E3 that determines the 
nature of the linkage in these chains [15] – a decision that 
is normally the prerogative of the E2, at least in reactions 
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involving RING-class E3s [22]. The linear ubiquitin chain 
E3 is now known to be composed of three proteins. The 
first two of these – the heme-oxidized IRP2 ubiquitin 
ligase-1 (HOIL-1, also known as HOIL-1L and RBCK1) 
and the HOIL-1-interacting protein (HOIP, also known 
as RNF31) – were identified as part of this multi-
component E3 by Kirisako et al. [15], who also coined the 
term linear ubiquitin chain assembly complex (LUBAC) 
for this novel type of E3.
Subsequent research, however, revealed that LUBAC 
also contains a third component, SHARPIN (SHANK-
associated RH domain interacting protein), whose 
carboxy-terminal region has high sequence similarity 
with the amino-terminal part of HOIL-1 [19-21]. The 
structural features of the three components of LUBAC 
and their interactions are schematically illustrated in 
Figure 1. All three contain ubiquitin-binding domains 
whereby they may bind to ubiquitin or to one another 
through ubiquitin-like (UBL) domains. HOIP is the 
central architectural component of the tripartite LUBAC, 
binding to both HOIL-1 and SHARPIN through their 
respective UBL domains. The stoichiometry of the three 
components that make up the 600 kDa LUBAC is 
currently unknown and it is also possible that complexes 
consisting of only two of the three factors exist [15]. In 
addition, it appears that in different cell types varying 
amounts of HOIL-1, HOIP and SHARPIN are present 
independently of the other LUBAC components. It is 
therefore possible that these proteins may also serve 
functions that are independent of LUBAC activity 
[19-21].
Several lines of evidence indicate that LUBAC 
generates exclusively linear ubiquitin chains: (i) LUBAC 
can generate ubiquitin chains with lysine-less (K0) 
ubiquitin in vitro [15,18,21]; (ii) LUBAC is unable to 
generate ubiquitin chains from amino-terminally tagged 
ubiquitin [15,19]; and (iii) mass spectrometric analysis of 
polyubiquitin chains generated in vitro by LUBAC reveals 
linear ubiquitin linkages [15].
Where is the ubiquitin ligase activity of LUBAC and 
how is it activated?
There are two classes of E3s: RING (really interesting 
new gene) or U-box-type E3s catalyze the E2-mediated 
transfer of ubiquitin to target proteins [23,24], whereas in 
the case of HECT (homologous with E6-associated 
protein C-terminus)-type E3s ubiquitin is first transferred 
to the E3 by the formation of a thioester bond, and then 
from the E3 to the substrate. Both HOIL-1 and HOIP 
contain a RING-in-between-RING (IBR)-RING (RBR) 
domain (Figure 1), and hence form part of the RBR 
subclass of RING-E3s, so in principle either HOIL-1 or 
Figure 1. Schematic representation of the LUBAC components, SHARPIN, HOIP and HOIL-1. There is significant sequence homology (45% 
identity) between the carboxyl terminus of SHARPIN and the amino terminus of HOIL-1, each of which contains a UBL and an NZF motif. HOIP is the 
catalytic subunit of the tripartite LUBAC with SHARPIN and HOIL-1 as accessory factors that bind via their respective UBL domains to the NZF2 and 
UBA domains of HOIP, respectively. HOIP, SHARPIN and HOIL-1 also bind to ubiquitin chains through NZF-mediated interactions. The functions of 
the ZnF domain of HOIP and the coiled-coil domain of SHARPIN are currently unknown. The RBR domain of HOIP, but not of HOIL-1, is responsible 
for linear ubiquitin chain generation by LUBAC. Arrows indicate confirmed interactions between the proteins. Abbreviations: ZnF, zinc finger; NZF, 
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HOIP could account for the ubiquitin ligase activity of 
LUBAC. However, the combination of recombinant 
SHARPIN and HOIL-1 cannot generate linear ubiquitin 
chains in vitro, whereas recombinant HOIP together with 
HOIL-1 or SHARPIN (or of course both) can; moreover, 
overexpression of these combinations is also capable of 
activating NF-kB, one of the key transcription factors 
activated by TNF (see below) [19-21].
This is in line with experiments showing that, despite 
the fact that HOIL-1 and HOIP both contain an RBR 
domain (Figure 1), it is the RBR of HOIP that mediates 
the formation of the linear ubiquitin linkage in these 
different complexes because the intact RBR of HOIP, but 
not of HOIL-1, is required for LUBAC activity [15]. 
Indeed, despite its containing an apparently complete 
RBR domain [25,26], no linear ubiquitination activity has 
so far been detected for recombinant wild-type HOIL-1 
in ubiquitination assays in vitro. It is possible, however, 
that interactions with partners other than HOIP and 
SHARPIN, or perhaps post-translational modification, 
may induce its activation.
If HOIP is the active E3 in LUBAC, what is the 
contribution of HOIL-1 and SHARPIN? The answer to 
this question and to the question of HOIL-1 E3 activity 
may lie in a mechanism recently reported for Parkin, 
another RBR-containing E3, which closely resembles 
HOIL-1 in domain structure [27,28]. Parkin is auto-
inhibited by its UBL and this auto-inhibition may be 
relieved by binding to a co-factor or a substrate [29]. The 
zinc finger and the UBL domains of HOIL-1 and 
SHARPIN are crucial for activation of the linear-
ubiquitin-generating activity of HOIP [16], and it may be 
that the binding of SHARPIN and/or HOIL-1 to HOIP 
relieves an auto-inhibition in HOIP in a way that is 
analogous to the activation of Parkin by binding to a 
partner (K Rittinger and B Stieglitz, personal 
communication). No qualitative differences have yet been 
discovered in the potential of SHARPIN and HOIL-1 to 
unleash the linear-ubiquitin-generating capacity of HOIP, 
although they seem likely to exist. It is tempting to 
speculate that SHARPIN and HOIL-1 may direct the 
linear ubiquitination activity of HOIP to different targets.
It remains to be determined whether there are binding 
partners for HOIL-1 other than HOIP and SHARPIN, 
and, if so, whether this results in HOIL-1-mediated 
generation of linear or other ubiquitin chain linkages. 
Recent results from Rachel Klevit and colleagues on 
Parkin and another RBR-domain-containing protein, 
human homologue of Ariadne (HHARI), may hint at the 
mechanism whereby LUBAC promotes the formation of 
ubiquitin chains. They showed that HHARI, and possibly 
also Parkin, functions as an HECT-like E3 ligase, through 
a conserved cysteine residue in the second RING domain, 
RING2, that accepts a charged ubiquitin in a thioester 
intermediate before transferring the bound ubiquitin to a 
substrate [30]. This insight into mechanism, however, 
cannot explain the specific generation of linear ubiquitin 
linkages by HOIP, because Parkin is known to generate 
K48- and K63-linked chains [31,32].
Clearly we are only just beginning to explore the 
biochemistry of linear ubiquitin chain formation by 
LUBAC, and much remains to be discovered about the 
specificity of this complex in the exclusive generation of 
linear ubiquitin chains, and the exact actions of the 
different components within the protein complex.
Linear ubiquitination in the TNF receptor pathway
Ubiquitination by K63- and K48-linked chains was 
already known, before the discovery of linear ubiquitin 
chains, to play an important part in the activation of NF-
kB, arguably the most crucial output of TNFR1 signaling. 
Activation of the TNFR1 pathway occurs when trimeric 
TNF crosslinks three TNFR1 monomers to initiate 
formation of the TNFR1 signaling complex (TNF-RSC). 
As schematically illustrated in Figure 2, TNFR1 activation 
results in the induction of gene activation by NF-kB and 
mitogen-activated protein kinases (MAPKs) and, 
depending on the strength of these gene-activatory 
signals, also in cell death, which can be either apoptotic 
(non-inflammatory) or necroptotic (inflammatory).
NF-kB is a central transcriptional regulator in the 
induction of immune response genes that, in the absence 
of activating signals, is located in the cytoplasm. 
Activation of NF-kB occurs through the action of a 
kinase complex, referred to as the IkB kinase (IKK) 
complex, which consists of two catalytic subunits, IKKa 
(IKK1) and IKKb (IKK2), and a critical regulatory subunit 
called NEMO (IKKg). This complex is required to 
phosphorylate the inhibitor of NF-kB (IkB), thereby 
inducing its degradation and releasing NF-kB to relocate 
to the nucleus and bind to the promoters of immune 
genes. The IKK complex is recruited to the TNF-RSC 
through NEMO, and this results in activation of the 
kinase activity of this complex. MAPKs are activated as a 
result of recruitment of the TAB/TAK complex into the 
TNF-RSC. Whilst the TAB/TAK complex is currently 
thought to be recruited exlusively to K63-linked chains 
within the TNF-RSC, the IKK complex can be recruited 
to this complex via linear chains and, albeit with lesser 
affinity, also via K63- and K11-linked chains [33].
LUBAC activity was first implicated in signaling from 
TNFR1 when TNF-mediated NF-kB activation was 
shown to be impaired in primary hepatocytes from 
HOIL-1 knockout mice, and LUBAC was shown to form 
part of the signaling complex that forms on binding of 
TNF by the receptor, and moreover to be crucial both to 
the stability of the TNF-RSC and in determining the 
outcome of TNF signaling [16-18]. How LUBAC 
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recruitment to the TNF-RSC influences signaling 
outcome is not known in detail, but it is known that 
NEMO, which is the regulatory component of the kinase 
complex that activates NF-kB, recognizes linear ubiquitin 
chains through its specialized ubiquitin-binding domain, 
UBAN (ubiquitin-binding domain present in ABINs and 
NEMO) [17,34]. The UBAN motif is known also to 
recognize ubiquitin chains with other linkages – in 
particular K63 chains, which are also present on 
components of the TNF-RSC, including on RIP1 [19]; 
but the UBAN of NEMO binds linear di-ubiquitin with a 
different topology and about 100-fold higher affinity than 
it does K63-linked di-ubiquitin. This suggests that the 
promotion of NF-kB activation by LUBAC following 
TNF stimulation may be due to linear ubiquitination of a 
component of the signaling complex whereby NEMO is 
recruited to, or retained in, the complex more effectively.
LUBAC also linearly ubiquitinates NEMO itself in the 
native TNF-RSC [19]. TNF-induced linear ubiquitination 
of NEMO preferentially occurs on K285 and K309, and in 
cells expressing a NEMO K285R/K309R mutant, NF-kB 
activation induced by LUBAC overexpression or by 
Figure 2. Model of TNFR1 signaling with and without LUBAC activity. Binding of trimeric TNF crosslinks the extracellular domains of three 
TNFR1 molecules and induces the formation of the TNF-RSC (also referred to as complex I). The tripartite LUBAC (ochre) is recruited to the TNF-
RSC in a TRADD-, TRAF2- and cIAP-dependent manner (left panel) [16,19]. LUBAC activity in the TNF-RSC results in linear ubiquitination of RIP1 
and NEMO [19] and enables the NF-kB and MAPK pathways to be activated to their full physiological extent. After a delay, and probably as a 
consequence of deubiquitination events at the membrane-bound TNF-RSC, the composition of the complex changes, and a second complex, 
complex II, appears in the cytosol [45]. Complex II (not shown) recruits FADD and caspase- 8, which are responsible for the induction of apoptosis, 
and includes RIP1 and RIP3, which mediate necroptosis. In the presence of LUBAC, however, the induction of cell death is prevented, probably by 
both stabilization of complex I by linear ubiquitination and the actions of genes induced by the NF-kB and MAPK pathways [16]. In the absence of 
SHARPIN (right panel), the other two LUBAC components are also drastically diminished, TNF-induced gene activation is attenuated and the TNF-
RSC is destabilised, resulting in enhanced complex II formation and, consequently, cell death induction by apoptosis and necroptosis. Note that we 
have drawn the ubiquitin chains as diubiquitins. The actual length of the individual ubiquitin chains attached to components of the TNF-RSC – or 
indeed to components of any other signaling complex – is currently unknown.
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stimulation with IL-1b was reduced [18]. The mechanism 
of linear-ubiquitination-induced NF-kB activation has 
not been solved, but current data indicate that binding of 
NEMO to linearly linked ubiquitin induces a 
conformational change in the helical structure of NEMO 
that may promote the kinase activity of the IKK complex 
[17,35]. Alternatively, recognition of linear chains by 
NEMO conjugated to the NEMO molecules of other IKK 
complexes could bring the kinase domains of the 
respective IKK complexes into close proximity, thereby 
enabling trans-autophosphorylation [17], a process 
similar to the one that occurs between receptor tyrosine 
kinases when activated by ligand-induced dimerization.
Together, these findings indicate a functional role for 
linear ubiquitination in full gene activation by the 
signaling pathways triggered by TNF in vivo. In the 
absence of LUBAC components the TNF-RSC still forms 
and activation of NF-kB still occurs, albeit at significantly 
reduced levels [20,21]. Experiments with HOIP-deficient 
cells will be needed to strictly corroborate these findings, 
but it is likely that the NF-kB activation that still occurs 
in the absence of LUBAC is mediated by K63- and/or 
K11-linked chains, which are also present in the native 
TNF-RSC [19] and can also bind or be attached to 
NEMO [33,36-39].
Absence of LUBAC components also renders cells 
sensitive to TNF-induced cell death [16,20]. 
Intriguigingly, this cell death is not only apoptotic [19,20] 
but also necroptotic [19]. Importantly, this is also true of 
primary keratinocytes obtained from young, non-
diseased cpdm mice. These mice, which are genetically 
deficient in SHARPIN and thus lack functional LUBAC 
complexes [19], have played a central part in the 
discovery of the physiological function of LUBAC. They 
present with stark immune system developmental 
abnormalities, and develop a chronic multi-organ 
inflammatory syndrome with strong manifestation in the 
skin (hence the name of this mutation: chronic 
proliferative dermatitis (cpdm)) at about 4 to 6 weeks of 
age [40]. The inflammatory syndrome that characterizes 
cpdm mice is apparently paradoxical, because it is 
generally thought that aberrantly high TNF-induced gene 
activation is the source of inflammation induced by this 
cytokine. Our finding that TNF stimulation results in 
aberrant death of cpdm-derived cells, and that this cell 
death has both an apoptotic and a necroptotic (and thus 
inflammatory) component [19,41,42], suggested a 
different explanation: namely, that the inflammation in 
cpdm mice could be due to inflammatory cell death 
consequent on the absence of SHARPIN-requiring 
LUBAC activity. To investigate this possibility, we crossed 
cpdm mice with TNF-deficient mice, and were able to 
show that even partial genetic ablation of TNF prevented 
the formation of inflammatory lesions in cpdm mice, 
indicating that TNF-induced cell death is indeed 
causative for the inflammatory phenotype that 
characterizes these mice [19]. It is possible that secondary 
necrosis, which can occur as a consequence of apoptosis, 
may also contribute to inflammation in cpdm mice.
Hence, linear ubiquitination is implicated in two 
different physiological processes: the development of the 
immune system and the prevention of chronic 
inflammation, where the latter effect is achieved through 
interference with TNF-induced cell death. Whether the 
aberrant cell death in the absence of LUBAC is due to 
reduced gene-inducing capacity of TNF, to a more direct 
effect of absence of linear ubiquitin chains from the 
signaling complexes induced by TNF, or perhaps to a 
combination of both these effects remains to be 
established. Our current suggestion for the contribution 
of LUBAC to these pathways is schematically illustrated 
in Figure 2.
What next?
The discovery of linear ubiquitin chains and their specific 
ligase complex (LUBAC) has sparked considerable 
interest in the physiological roles of these cellular signals. 
Rapid progress in the delineation of protein assemblies 
involved in conjugation and recognition of linear 
ubiquitination in vivo have provided a platform for 
addressing new challenges in the field. Among them are 
proteomic studies of the linear ubiquitinome – the set of 
linearly ubiquitinated proteins in cells; analysis at atomic 
resolution of protein complexes implicated both in 
conjugation and recognition functions; and the possibility 
of finding novel regulatory components of LUBAC by 
identification of regulatory principles of LUBAC 
functions and of novel linear ubiquitin binding domains 
(LUBIDs). Interestingly, the new LUBIDs include the zinc 
finger (ZF) domain of HOIL-1, which has recently been 
shown to recognize specifically linear ubiquitin chains 
[43]. One of the greatest challenges, however, will be to 
understand how the different types of ubiquitin linkages 
cooperate to achieve the exact physiologically required 
signaling output, and how this is regulated at the level of 
the receptor signaling complexes. Identifying the 
individual ubiquitination events that occur in the TNF-
RSC and determining their respective physiological roles 
is likely to provide valuable insight into biochemistry and 
function of different types of ubiquitinations, including 
linear ubiquitination [44].
Published: 15 March 2012
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